文献速递乳腺癌放疗放疗物理与技术

患者与治疗特征对左侧乳腺癌辅助放疗中心脏和肺剂量的影响

Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer.
PubMed 文献 · Radiat Oncol · 2019-08-28

该研究分析332例2013–2018年左侧乳腺癌辅助放疗患者,发现淋巴结放疗显著增加心脏和肺剂量,尤其内乳淋巴结放疗;无淋巴结放疗时IMRT/VMAT较3DCRT增加左肺剂量;肺体积与心脏剂量负相关,BMI与平均心脏剂量弱正相关。

要点

  • 淋巴结放疗显著增加平均心脏剂量、左肺平均剂量和左肺V20Gy。
  • 内乳淋巴结放疗较仅锁骨上/腋窝淋巴结放疗进一步增加器官剂量。
  • 无淋巴结放疗时IMRT/VMAT较3DCRT增加左肺剂量,需权衡获益与肺剂量。

核心结论

  • 左侧乳腺癌辅助放疗中,淋巴结放疗与心脏和肺剂量显著增加相关,尤其内乳淋巴结放疗。
  • IMRT/VMAT用于乳腺或胸壁放疗的潜在优势需权衡左肺剂量中度增加。

研究设计与样本

  • 回顾性分析332例2013–2018年接受左侧乳腺癌放疗的女性患者。
  • 从治疗计划收集平均心脏剂量、左肺平均剂量及心脏/肺V20Gy。
  • 按放疗技术(3DCRT、IMRT、VMAT)和靶区体积(包括淋巴结放疗)分层。
  • 采用相关分析评估患者特征(BMI、心脏和肺体积)的影响。

主要发现

  • 111例接受淋巴结放疗者较未接受者平均心脏剂量升高(中位4.6 vs. 3.3 Gy;p < .01)。
  • 淋巴结放疗者左肺平均剂量升高(14.8 vs. 7.7 Gy;p < .01),左肺V20Gy升高(30.0% vs. 14.4%;p < .01)。
  • 内乳淋巴结放疗较仅锁骨上±腋窝淋巴结放疗进一步增加剂量(p < .01;平均心脏剂量6.9 vs. 4.2 Gy)。
  • 221例无淋巴结放疗者中,IMRT/VMAT较3DCRT左肺平均剂量升高(9.1 vs. 7.4 Gy,p < .01),V20Gy升高(18.8% vs. 14.0%,p < .01)。
  • 总肺体积与平均心脏剂量(r = -0.38;p < .01)和心脏V20Gy(r = -0.37;p < .01)负相关,BMI与平均心脏剂量弱正相关(r = 0.27;p < .01)。

临床怎么用

  • 左侧乳腺癌辅助放疗计划时应关注淋巴结放疗尤其是内乳淋巴结放疗对心脏和肺剂量的影响。
  • 无淋巴结放疗时选择IMRT/VMAT需评估左肺剂量增加的风险。
  • 患者肺体积和BMI可能影响心脏剂量,计划设计时可参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The heart and lungs are routinely exposed to incidental irradiation during adjuvant radiotherapy (RT) of breast cancer. We analyzed the impact of patient and treatment characteristics on heart and lung dose in left-sided breast RT. METHODS: We analyzed 332 female patients treated with left-sided breast RT between 2013 and 2018. Mean heart dose (MHD), left mean lung dose (MLD) and heart / lung V20Gy were collected from treatment plans. Patients were stratified by RT technique (3D-conformal RT, 3DCRT; intensity-modulated RT, IMRT; volumetric modulated arc therapy, VMAT) and target volumes, including lymph node RT (LN-RT). Patient characteristics (body mass index (BMI), heart and lung volume) were assessed using correlation analyses. RESULTS: LN-RT was performed in 111 patients with increased MHD (median 4.6 vs. 3.3 Gy; p < .01), left MLD (14.8 vs. 7.7 Gy; p < .01) and left lung V20Gy (30.0% vs. 14.4%; p < .01) compared to treatment without LN-RT. Internal mammary LN-RT further increased organ doses compared to RT involving only supraclavicular +/- axillary LN (p < .01 for all values; MHD 6.9 vs. 4.2 Gy). In 221 patients treated without LN-RT, IMRT/VMAT was associated with higher left lung doses (MLD 9.1 vs. 7.4 Gy, p < .01; V20Gy 18.8% vs. 14.0%, p < .01) compared to 3DCRT. A negative correlation between total lung volume and both MHD (r = - 0.38; p < .01) and heart V20Gy (r = - 0.37; p < .01), as well as a weak positive correlation of BMI and MHD (r = 0.27; p < .01) were observed. CONCLUSIONS: In adjuvant RT for left-sided breast cancer, LN-RT is associated with a marked increase in heart and lung doses, particularly with internal mammary LN-RT. Potential advantages of IMRT/VMAT for breast or chest wall RT need to be weighed against a moderately increased lung dose.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Finazzi T, Nguyen VT, Zimmermann F, et al. Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer. Radiat Oncol. 2019. PMID: 31462267. doi:10.1186/s13014-019-1364-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。